David Moore joins Corvus board as Class III director through 2028; gets 30K option grant

Corvus Pharmaceuticals, Inc.

David Moore appointed as Class III director, term expires at 2028 annual meeting.
Moore will serve on Compensation Committee ($6K/yr) and Nominating Committee ($4K/yr).
Receives $35K annual retainer and initial option to purchase 30,000 shares of common stock.
Appointment effective October 2, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.